Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atipamezole and Caffeine for Reversal of Dexmedetomidine Anesthesia
NCT04942340Phase 1Withdrawn
- Sponsor
- University of Chicago
- Start
- May 2023
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing Atipamezole & Caffeine with Placebo Control (2 arms). Primary endpoint: Time from drug injection completion to awakening at 1 day. Planned start May 2023; status: withdrawn.
02
Drugs
atipamezolecaffeine
Beyond the preview
Go deeper on NCT04942340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04942340.